CAR-T Therapy Trials for Multiple Myeloma Face FDA Scrutiny After Early Deaths
Boston, MA – The Food and Drug Administration (FDA) has raised concerns about early deaths in clinical trials for CAR-T cell therapies in multiple myeloma patients. The trials in question involve Johnson & Johnson’s Carvykti and Legend Biotech’s Carvykti, as well as Bristol Myers Squibb’s Abecma. CAR-T cell therapies have shown promise in treating certain types of cancer by genetically modifying a patient’s own immune cells to attack cancer cells. However, the FDA is now …